Evidence map›Paper›PMID 40685652›Full record

ArticleThe Libyan journal of medicine2025

Androgen receptor expression in triple negative breast cancer: an Algerian population study.

Amel Hedjem, Amal Kouchkar, Amel Ladjeroud, Nacera Zerrouki, Fatima Benaissa, Nasir A Ibrahim, Mohammed Saad Aleissa, Nosiba S Basher, Assia Derguini, Takfarinas Idres and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Libyan journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amel HedjemDepartment of Biology, Faculty of Sciences, University M'hamed Bougara, Boumerdes, Algeria.
Amal KouchkarDepartment of Pathology, Pierre and Marie Curie Cancer Center, Algiers, Algeria.
Amel LadjeroudDepartment of Medical, Pierre and Marie Curie Cancer Center, Algiers, Algeria.
Nacera ZerroukiLaboratoire Ressources Naturelles, University Mouloud Maameri, Tizi Ouzou, Algeria.
Fatima BenaissaLaboratory of Biomathematics, Biophysics, Biochemistry and Scientometry L3BS, University of Bejaia, Bejaïa, Algeria.
Nasir A IbrahimBiology Department, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Mohammed Saad AleissaBiology Department, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Nosiba S BasherBiology Department, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Assia DerguiniMicrobial Ecology Laboratory, FSNV, Abderrahmane MIRA University, Bejaïa, Algeria.
Takfarinas IdresLaboratory for Livestock Animal Production and Health Research, Rabie Bouchama National Veterinary School of Algiers, Algiers, Algeria.
Karim HoualiLaboratory of Analytic Biochemistry and Biotechnology (LABAB), Department of Biochemistry and Microbiology, Faculty of Biological and Agronomic Sciences, Mouloud Mammeri University, Tizi-Ouzou, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer characterized by the absence of estrogen and progesterone receptors and the lack of HER2 overexpression. TNBC is highly heterogeneous, complicating the identification of new therapeutic targets. However, the expression of the androgen receptor (AR) in the luminal androgen receptor (LAR TNBC) subgroup has opened the door to alternative therapeutic approaches. This study aimed to assess AR expression and correlate it with clinicopathological factors in 160 early-stage TNBC patients treated from February 2015 to February 2017. Our findings reveal that AR expression is observed in 16.87% (27/160) of ≥1% AR positivity cases. Moreover, a significant 12.5% (20/160) was found in ≥10% AR positive cases. Positive AR expression was inversely correlated with a high Ki-67 proliferation index and with the basal immunophenotype. The five-year survival rate for our cohort was 83.12%, and no significant association between AR expression and overall survival was observed (

Indexed as

Receptors, AndrogenTriple Negative Breast NeoplasmsAdultAgedAlgeriaBiomarkers, TumorFemaleHumansKi-67 AntigenMiddle AgedSurvival RateAR protein, humanBiomarkers, TumorKi-67 AntigenReceptors, Androgenandrogen receptorchemotherapyestrogen receptorHER2TNBC classificationTriple-negative breast cancer

Identifiers

PMID40685652
PMCPMC12281659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.